Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension

Figure 3 A: Plasmatic 6-keto PGF_1α concentrations (expressed in ng/mL): ^bP < 0. 01 vs ShP (placebo); ^aP < 0.05 vs PHP (placebo); ^cP < 0.05 vs PHP (placebo); B: Plasmatic TXB₂ concentrations (expressed in ng/mL): ^bP < 0.001 vs PHP (placebo); ^aP < 0.05 vs ShP (NS-398) and P < 0.001 vs PHAs (placebo); C: Plasmatic PGE₂ concentrations (expressed in ng/mL): ^aP < 0.05 vs PHP (placebo); D: Plasmatic LTB₄ concentrations (expressed in ng/mL).